TRANSMITTED HIV-1 DRUG RESISTANCE IN THE START STUDY USING NEXT GENERATION SEQUENCING
暂无分享,去创建一个
M. Kozal | J. Lundgren | A. Tostevin | D. Dunn | A. Cozzi-Lepri | M. Gompels | A. Pinto | J. Baxter | R. Marvig | Shweta Sharma | Marc Bennedbæk
[1] T. F. Rinke de Wit,et al. Low-abundance drug-resistant HIV-1 variants in antiretroviral drug-naïve individuals: A systematic review of detection methods, prevalence, and clinical impact. , 2019, The Journal of infectious diseases.
[2] R. Shafer,et al. 2019 update of the drug resistance mutations in HIV-1. , 2019, Topics in antiviral medicine.
[3] R. Shafer,et al. Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] V. Calvez,et al. Impact of next generation sequencing defined HIV pre-treatment drug resistance on virological outcomes in the ANRS 12249 treatment as prevention trial , 2018 .
[5] Orna Mor,et al. Comparison between next-generation and Sanger-based sequencing for the detection of transmitted drug-resistance mutations among recently infected HIV-1 patients in Israel, 2000–2014 , 2017, Journal of the International AIDS Society.
[6] Michael Huber,et al. MinVar: A rapid and versatile tool for HIV-1 drug resistance genotyping by deep sequencing. , 2017, Journal of virological methods.
[7] Ross J. Harris,et al. Enhanced surveillance of HIV-1 drug resistance in recently infected MSM in the UK , 2017, The Journal of antimicrobial chemotherapy.
[8] H. Lane,et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. , 2015, The New England journal of medicine.
[9] J. Lundgren,et al. Global HIV‐1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial , 2015, HIV medicine.
[10] Richard J Orton,et al. Distinguishing low frequency mutations from RT-PCR and sequence errors in viral deep sequencing data , 2015, BMC Genomics.
[11] Karin J. Metzner,et al. Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing , 2014, The Journal of antimicrobial chemotherapy.
[12] Jeroen Aerssens,et al. VirVarSeq: a low-frequency virus variant detection pipeline for Illumina sequencing using adaptive base-calling accuracy filtering , 2015, Bioinform..
[13] M. Kozal,et al. Low-Frequency NNRTI-Resistant HIV-1 Variants and Relationship to Mutational Load in Antiretroviral-Naïve Subjects , 2014, Viruses.
[14] Anne-Mieke Vandamme,et al. Automated subtyping of HIV-1 genetic sequences for clinical and surveillance purposes: performance evaluation of the new REGA version 3 and seven other tools. , 2013, Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases.
[15] K. Metzner,et al. Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection. , 2013, The Journal of infectious diseases.
[16] D. Webster,et al. Persistence of HIV-1 Transmitted Drug Resistance Mutations , 2013, The Journal of infectious diseases.
[17] Ann M. Dennis,et al. Prevalence of Transmitted Antiretroviral Drug Resistance Differs Between Acutely and Chronically HIV-Infected Patients , 2012, Journal of acquired immune deficiency syndromes.
[18] Astrid Gall,et al. Universal Amplification, Next-Generation Sequencing, and Assembly of HIV-1 Genomes , 2012, Journal of Clinical Microbiology.
[19] C. Boucher,et al. Temporal changes in the epidemiology of transmission of drug-resistant HIV-1 across the world. , 2012, AIDS reviews.
[20] David L. Robertson,et al. Analysis of high-depth sequence data for studying viral diversity: a comparison of next generation sequencing platforms using Segminator II , 2012, BMC Bioinformatics.
[21] M. Wainberg,et al. Transmission dynamics of the M184V drug resistance mutation in primary HIV infection. , 2011, The Journal of antimicrobial chemotherapy.
[22] K. Metzner,et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. , 2011, JAMA.
[23] W. Heneine,et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.–2006 , 2010, AIDS.
[24] A. Wensing,et al. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. , 2010, Antiviral research.
[25] Anne-Mieke Vandamme,et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update , 2009, PloS one.
[26] Gregory S Turenchalk,et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. , 2009, The Journal of infectious diseases.
[27] Michael Monsour,et al. Minority HIV-1 Drug Resistance Mutations Are Present in Antiretroviral Treatment–Naïve Populations and Associate with Reduced Treatment Efficacy , 2008, PLoS medicine.
[28] D. Richman,et al. Persistence of Transmitted Drug Resistance among Subjects with Primary Human Immunodeficiency Virus Infection , 2008, Journal of Virology.
[29] M. Kozal,et al. Natural Polymorphism of the HIV-1 Integrase Gene and Mutations associated with Integrase Inhibitor Resistance , 2007, Antiviral therapy.
[30] Allan E. Rodriguez,et al. Prevalence of Antiretroviral Drug Resistance and Resistance-Associated Mutations in Antiretroviral Therapy-Naïve HIV-Infected Individuals from 40 United States Cities , 2007, HIV clinical trials.
[31] A. Geretti. Epidemiology of antiretroviral drug resistance in drug-naïve persons , 2007, Current opinion in infectious diseases.
[32] W. Heneine,et al. The Fitness Cost of Mutations Associated with Human Immunodeficiency Virus Type 1 Drug Resistance Is Modulated by Mutational Interactions , 2006, Journal of Virology.
[33] Tommy F. Liu,et al. Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[34] D. Pillay,et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy , 2006, AIDS.
[35] M. Kozal,et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[36] Elizabeth Connick,et al. Antiretroviral-drug resistance among patients recently infected with HIV. , 2002, The New England journal of medicine.